OBIO Earnings & Financial Statements
Orchestra BioMed Holdings, Inc.
$5.64
-$0.08(-1.40%)
50
Overall
60
Value
66
Tech
26
Quality
Market Cap
$338.99M
Volume
222.88K
52W Range
$3.06 - $6.50
Target Price
$12.50
OBIO earnings and financial statements: Orchestra BioMed Holdings, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
OBIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $33.48M | $2.64M | $2.76M | $3.53M | - |
| Cost of revenue | $190.0K | $204.0K | $186.0K | $211.0K | - |
| Operating income | -$51.81M | -$64.30M | -$51.51M | -$32.66M | -$394.8K |
| EBITDA | -$50.40M | -$63.39M | -$46.69M | -$32.44M | -$394.8K |
| Net income | -$52.70M | -$61.02M | -$49.12M | -$33.61M | -$378.8K |
| EPS (diluted) | $-1.11 | $-1.66 | $-1.48 | $-0.17 | $-0.02 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $114.86M | $76.17M | $95.21M | $95.57M | $161.82M |
| Total liabilities | $51.48M | $43.22M | $27.17M | $43.04M | $165.77M |
| Shareholders’ equity | $53.55M | $32.96M | $68.04M | $52.53M | -$3.94M |
| Cash and equivalents | $34.69M | $22.26M | $30.56M | $19.78M | $1.75M |
| Long-term debt | $15.20M | $15.98M | $1.04M | $11.17M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$48.96M | -$50.56M | -$46.13M | -$29.29M | -$19.43M |
| Capital expenditure | -$489.0K | -$289.0K | -$78.0K | -$591.0K | -$274.0K |
| Free cash flow | -$49.45M | -$50.85M | -$46.20M | -$29.88M | -$19.70M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OBIO | $5.64 | -1.4% | 222.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Orchestra BioMed Holdings, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW